首页|期刊导航|癌症生物学与医学（英文版）|From residual risk to precision intervention:the evolving role of minimal residual disease in breast cancer management

From residual risk to precision intervention:the evolving role of minimal residual disease in breast cancer management

Junnan Xu Kun Fang Xiaoxi Li Li Han Shulan Sun Tao Sun

癌症生物学与医学（英文版）2025，Vol.22Issue(12)：1493-1514,22.

癌症生物学与医学（英文版）2025，Vol.22Issue(12)：1493-1514,22.DOI:10.20892/j.issn.2095-3941.2025.0431

From residual risk to precision intervention:the evolving role of minimal residual disease in breast cancer management

Junnan Xu ¹Kun Fang ²Xiaoxi Li ³Li Han ⁴Shulan Sun ³Tao Sun⁵

作者信息

1. Department of Breast Medicine,Cancer Hospital of Dalian University of Technology,Cancer Hospital of China Medical University,Liaoning Cancer Hospital&Institute,Shenyang 110042,China||Department of Pharmacology,Cancer Hospital of China Medical University,Shenyang 110042,China
2. Department of Pharmacology,Cancer Hospital of China Medical University,Shenyang 110042,China||Central Laboratory,Cancer Hospital of Dalian University of Technology,Cancer Hospital of China Medical University,Liaoning Cancer Hospital&Institute,Shenyang 110042,China
3. Central Laboratory,Cancer Hospital of Dalian University of Technology,Cancer Hospital of China Medical University,Liaoning Cancer Hospital&Institute,Shenyang 110042,China
4. Medicine Center,Kanghui Biotechnology Inc,Shenyang 110000,China
5. Department of Breast Medicine,Cancer Hospital of Dalian University of Technology,Cancer Hospital of China Medical University,Liaoning Cancer Hospital&Institute,Shenyang 110042,China
折叠

摘要

关键词

Circulating tumor DNA/minimal residual disease/breast cancer/tumor-informed MRD/precision management

Key words

Circulating tumor DNA/minimal residual disease/breast cancer/tumor-informed MRD/precision management

引用本文复制引用

Junnan Xu,Kun Fang,Xiaoxi Li,Li Han,Shulan Sun,Tao Sun..From residual risk to precision intervention:the evolving role of minimal residual disease in breast cancer management[J].癌症生物学与医学（英文版）,2025,22(12):1493-1514,22.

基金项目

This work was supported by the National Natural Science Foundation of China(Grant No.82373113,XJ),Shenyang Breast Cancer Clinical Medical Research Center(Grant No.2020-48-3-1,ST),Shenyang Public Health R&D Special Project(Grant No.22-321-31-04,ST),and Liaoning Revitalization Talents Program(Grant No.XLYC1907160,XJ). （Grant No.82373113,XJ）

癌症生物学与医学（英文版）

ISSN：2095-3941

访问量0

下载量0

段落导航